Loading
A Chinese screening cohort testing one blood test for three digestive cancers that are common in Shandong.
DECIPHER-GASTRO (NCT07106424) is an observational study sponsored by Shandong Cancer Hospital and Institute. It is a liquid biopsy early screening cohort for gastrointestinal cancers.
The registry record, read on 29 October 2026, gives its status as recruiting, with an estimated 4,000 participants, a start on 10 September 2024 and primary completion expected on 10 September 2028.
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/